SCHEMBL5539302

SCHEMBL5539302

CCC(=O)OCc1cscn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PKM P14618 1/20 0.40
PDE10A Q9Y233 1/20 0.37
ALDH1A1 P00352 3/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HPGD P15428 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
BLM P54132 1/20 0.36
WRN Q14191 1/20 0.36
HIF1A Q16665 1/20 0.36
GRM5 P41594 1/20 0.36
KDM4E B2RXH2 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
CTSK P43235 1/20 0.34
ALOX5 P09917 1/20 0.34
ACACB O00763 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3999262 0.83 PKM (0.45) MAPK1NPSR1PKMPDE10AALDH1A1
Butane SCHEMBL7279880 0.83 MAPK1 (0.37) MAPK1NPSR1PKMPDE10AALDH1A1
SCHEMBL3338970 0.82 MAPK1 (0.43) MAPK1NPSR1PKMPDE10AALDH1A1
SCHEMBL27817856 0.79 CTSK (0.40) MAPK1NPSR1PKMPDE10AALDH1A1
SCHEMBL7279888 0.76 MAPK1 (0.40) MAPK1NPSR1PKMALDH1A1LMNA
SCHEMBL27901729 0.75 MAPK1 (0.36) MAPK1NPSR1PKMPDE10AALDH1A1
SCHEMBL3334929 0.74 MAPK1 (0.41) MAPK1NPSR1PKMGAAGRM5
SCHEMBL28076009 0.74 PKM (0.47) MAPK1NPSR1PKMPDE10AALDH1A1
SCHEMBL5543425 0.74 CTSK (0.47) MAPK1NPSR1PKMALDH1A1LMNA
Ethoxycarbonyl Group SCHEMBL27832029 0.74 MAPK1 (0.36) MAPK1NPSR1PKMPDE10AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPK1 1392/4885NPSR1 747/4885PKM 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.